Cancer Research and Treatment

Original Articles

Impact of Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers and Thiazide Diuretics on Survival of Ovarian Cancer Patients: Min Ae Cho, Soo Young Jeong, Insuk Sohn, Myeong-Seon Kim, Jun Hyeok Kang, E Sun Paik, Yoo-Young Lee, Chel Hun Choi; Cancer Res Treat. 2020;52(2):645-654. Published online January 16, 2020; DOI: https://doi.org/10.4143/crt.2019.509

Abstract PDF Supplementary Material PubReader ePub

Purpose
We investigated the impact of four types of antihypertensive medications, angiotensin receptor blockers (ARBs), beta blockers (BBs; both selective and non-selective), calcium channel blockers (CCBs), and thiazide diuretics (TDs) on survival outcomes in epithelial ovarian cancer (EOC).
Materials and Methods
A single-institutional retrospective chart review of 878 patients with EOC was performed. Survival was compared according to use of the four antihypertensive medications during primary treatment. Propensity score matching (ratio 1:3) was performed to control possible associated covariates, such as age, International Federation of Gynecology and Obstetrics stage, residual status after primary debulking surgery, and co-morbidity.
Results
Among 878 patients, 56 patients (6.4%) were ARB users, 62 (7.1%) were BB users, 107 (12.2%) were CCBs users and 32 (3.6%) used TDs. Median progression-free survival (PFS) for ARB, BB, and CCB users was 37.8, 27.2, and 23.6 months compared with 33.6 months for non-users. ARB was associated with 35% decreased risk of disease progression (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.42 to 0.99; p=0.046) in multivariate analysis. After propensity score matching, median PFS for ARB users was 37.8 months and ARB use remained to be associated with lower recurrence rate in univariate (p=0.035) and multivariate analysis (HR, 0.60; 95% CI, 0.39 to 0.93; p=0.022).
Conclusion
In this study, ARBs use during primary treatment is associated with lower recurrence in EOC patients. However, CCBs, BBs, and TDs did not show beneficial impact.

Citations

Citations to this article as recorded by

Evaluation of antihypertensive medications use and survival in patients with ovarian cancer: a population-based retrospective cohort study
Rūta Everatt, Irena Kuzmickienė, Birutė Brasiūnienė, Ieva Vincerževskienė, Birutė Intaitė, Saulius Cicėnas, Ingrida Lisauskienė
BMC Women's Health.2024;[Epub] CrossRef
Advanced progress of the relationship between renin–angiotensin–aldosterone system inhibitors and cancers
Ruixing Zhang, Hongtao Yin, Mengdi Yang, Jinjin Liu, Donghu Zhen, Zheng Zhang
Journal of Hypertension.2024; 42(11): 1862. CrossRef
Impact of ACEI/ARB use on the survival of hypertensive patients with cancer: A meta‑analysis
Yao Xiao, Xinlong Chen, Wancheng Li, Xin Li, Wence Zhou
Oncology Letters.2024;[Epub] CrossRef
Renin-Angiotensin-Aldosterone System Inhibitors and Development of Gynecologic Cancers: A 23 Million Individual Population-Based Study
Nhi Thi Hong Nguyen, Phung-Anh Nguyen, Chih-Wei Huang, Ching-Huan Wang, Ming-Chin Lin, Min-Huei Hsu, Hoang Bui Bao, Shuo-Chen Chien, Hsuan-Chia Yang
International Journal of Molecular Sciences.2023; 24(4): 3814. CrossRef
Association of Hypertension and Breast Cancer: Antihypertensive Drugs as an Effective Adjunctive in Breast Cancer Therapy
Yuanyuan Fan, Nazeer Hussain Khan, Muhammad Farhan Ali Khan, MD Faysal Ahammad, Tayyaba Zulfiqar, Razia Virk, Enshe Jiang
Cancer Management and Research.2022; Volume 14: 1323. CrossRef
The effect of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors on progression of gastric cancer: systematic review and meta-analysis
Seyed Ali Mehrdad, Farshad Mirzavi, Seyed Mohammad Reza Seyedi, Ahmad Asoodeh
Anti-Cancer Drugs.2022; 33(10): 983. CrossRef
Repurposing approved drugs for cancer therapy
Catherine H Schein
British Medical Bulletin.2021; 137(1): 13. CrossRef
Norepinephrine inhibits migration and invasion of human glioblastoma cell cultures possibly via MMP-11 inhibition
Jing Zhong, Weiran Shan, Zhiyi Zuo
Brain Research.2021; 1756: 147280. CrossRef
Antihypertensive Drug Use and the Risk of Ovarian Cancer Death among Finnish Ovarian Cancer Patients—A Nationwide Cohort Study
Eerik E. E. Santala, Miia Artama, Eero Pukkala, Kala Visvanathan, Synnöve Staff, Teemu J. Murtola
Cancers.2021; 13(9): 2087. CrossRef
The Use of Antihypertensive Drugs as Coadjuvant Therapy in Cancer
José A. Carlos-Escalante, Marcela de Jesús-Sánchez, Alejandro Rivas-Castro, Pavel S. Pichardo-Rojas, Claudia Arce, Talia Wegman-Ostrosky
Frontiers in Oncology.2021;[Epub] CrossRef
Post-Diagnostic Beta Blocker Use and Prognosis of Ovarian Cancer: A Systematic Review and Meta-Analysis of 11 Cohort Studies With 20,274 Patients
Zhao-Yan Wen, Song Gao, Ting-Ting Gong, Yu-Ting Jiang, Jia-Yu Zhang, Yu-Hong Zhao, Qi-Jun Wu
Frontiers in Oncology.2021;[Epub] CrossRef
Stress Hormones: Emerging Targets in Gynecological Cancers
Guoqiang Chen, Lei Qiu, Jinghai Gao, Jing Wang, Jianhong Dang, Lingling Li, Zhijun Jin, Xiaojun Liu
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef
The Effect of Local Renin Angiotensin System in the Common Types of Cancer
Moudhi Almutlaq, Abir Abdullah Alamro, Hassan S. Alamri, Amani Ahmed Alghamdi, Tlili Barhoumi
Frontiers in Endocrinology.2021;[Epub] CrossRef
Does sympathetic nervous system modulate tumor progression? A narrative review of the literature
Ioannis Stavropoulos, Angelos Sarantopoulos, Anastasios Liverezas
Journal of Drug Assessment.2020; 9(1): 106. CrossRef

14,233 View
163 Download
18 Web of Science
14 Crossref

Pretreatment Lymph Node Metastasis as a Prognostic Significance in Cervical Cancer: Comparison between Disease Status: Soo Young Jeong, Hyea Park, Myeong Seon Kim, Jun Hyeok Kang, E Sun Paik, Yoo-Young Lee, Tae Joong Kim, Jeong Won Lee, Byoung-Gie Kim, Duk Soo Bae, Chel Hun Choi; Cancer Res Treat. 2020;52(2):516-523. Published online October 29, 2019; DOI: https://doi.org/10.4143/crt.2019.328

Abstract PDF Supplementary Material PubReader ePub

Purpose
Lymph node metastasis (LNM) is the most significant prognostic factor in cervical cancer that was recently incorporated into the International Federation of Gynecology and Obstetrics (FIGO) staging system. This study was performed to evaluate whether the prognostic significance of LNM differs according to disease status.
Materials and Methods
Patients with FIGO stage IB or higher cervical cancer who had pretreatment computed tomography and/or magnetic resonance imaging studies as well as long-term follow-up were enrolled in this retrospective study. The hazard ratio (HR) of Cox regression was used to determine the prognostic significance of LNM. The HRs were compared between the different tumor groups (based on stage, histology, tumor size, primary treatment, age, parametrium involvement, and lymphovascular space invasion).
Results
A total of 970 patients treated between January 1999 and December 2007 were included. The pretreatment LNM had prognostic significance in patients with stage IB1/IIA (HR for progression-free survival 2.10, p=0.001; HR for overall survival 1.99, p=0.005). However, the significance gradually decreased or disappeared with advancing stages. Similarly, the prognostic significance of the pretreatment LNM decreased with advancing disease status, including old age, parametrial involvement or lymphovascular space involvement. In contrast, the tumor size was associated with the prognostic significance of LNM with advancing status. The significance of the clinical LNM did not reflect the significance of the clinical stage. In contrast, the tumor size, parametrial involvement, and significance of the pathologic LNM reflected the clinical stage.
Conclusion
In patients with cervical cancer, pretreatment LNM on imaging has different clinical significance depending on the tumor status.

Citations

Citations to this article as recorded by

Development of cervical intraepithelial neoplasia and invasive cervical cancer due to oxidative stress
Amir Asotić, Memić Asotić, Muhamed Memić, Kerim Asotić, Amra Asotić
Sanamed.2024; 19(1): 39. CrossRef
Investigating and Analyzing Prognostic Factors and Their Impact on Recurrent Cervical Cancers
Ashish Uke, Shweta B Dahake, Anurag Luharia, Monika Luharia, Gaurav V Mishra, Chanrashekhar Mahakalkar
Cureus.2024;[Epub] CrossRef
Based on 3D-PDU and clinical characteristics nomogram for prediction of lymph node metastasis and lymph-vascular space invasion of early cervical cancer preoperatively
Shuang Dong, Yan-Qing Peng, Ya-Nan Feng, Xiao-Ying Li, Li-Ping Gong, Shuang Zhang, Xiao-Shan Du, Li-Tao Sun
BMC Women's Health.2024;[Epub] CrossRef
Recent Advances in Cervical Cancer Management: A Review on Novel Prognostic Factors in Primary and Recurrent Tumors
Angela Santoro, Frediano Inzani, Giuseppe Angelico, Damiano Arciuolo, Emma Bragantini, Antonio Travaglino, Michele Valente, Nicoletta D’Alessandris, Giulia Scaglione, Stefania Sfregola, Alessia Piermattei, Federica Cianfrini, Paola Roberti, Gian Franco Za
Cancers.2023; 15(4): 1137. CrossRef
Identification of lymph node metastasis in pre‐operation cervical cancer patients by weakly supervised deep learning from histopathological whole‐slide biopsy images
Qingqing Liu, Nan Jiang, Yiping Hao, Chunyan Hao, Wei Wang, Tingting Bian, Xiaohong Wang, Hua Li, Yan zhang, Yanjun Kang, Fengxiang Xie, Yawen Li, XuJi Jiang, Yuan Feng, Zhonghao Mao, Qi Wang, Qun Gao, Wenjing Zhang, Baoxia Cui, Taotao Dong
Cancer Medicine.2023; 12(17): 17952. CrossRef
Roles of DWI and T2-weighted MRI volumetry in the evaluation of lymph node metastasis and lymphovascular invasion of stage IB–IIA cervical cancer
Y. Wang, X. Chen, H. Pu, Y. Yuan, S. Li, G. Chen, Y. Liu, H. Li
Clinical Radiology.2022; 77(3): 224. CrossRef
Risk Factor Assessment of Lymph Node Metastasis in Patients With FIGO Stage IB1 Cervical Cancer
Mu Xu, Xiaoyan Xie, Liangzhi Cai, Yongjin Xie, Qiao Gao, Pengming Sun
Frontiers in Oncology.2022;[Epub] CrossRef
Intravoxel Incoherent Motion (IVIM) MR Quantification in Locally Advanced Cervical Cancer (LACC): Preliminary Study on Assessment of Tumor Aggressiveness and Response to Neoadjuvant Chemotherapy
Miriam Dolciami, Silvia Capuani, Veronica Celli, Alessandra Maiuro, Angelina Pernazza, Innocenza Palaia, Violante Di Donato, Giusi Santangelo, Stefania Maria Rita Rizzo, Paolo Ricci, Carlo Della Rocca, Carlo Catalano, Lucia Manganaro
Journal of Personalized Medicine.2022; 12(4): 638. CrossRef
The prognostic significance of pretreatment squamous cell carcinoma antigen levels in cervical cancer patients treated by concurrent chemoradiation therapy and a comparison of dosimetric outcomes and clinical toxicities between tomotherapy and volumetric
Yuan-Kai Cheng, Shih-Hsun Kuo, Heng-Hsuan Yen, Jing-Hu Wu, Yu-Chieh Chen, Ming-Yii Huang
Radiation Oncology.2022;[Epub] CrossRef
What MRI-based tumor size measurement is best for predicting long-term survival in uterine cervical cancer?
Njål Lura, Kari S. Wagner-Larsen, David Forsse, Jone Trovik, Mari K. Halle, Bjørn I. Bertelsen, Øyvind Salvesen, Kathrine Woie, Camilla Krakstad, Ingfrid S. Haldorsen
Insights into Imaging.2022;[Epub] CrossRef
Clinical value of MRI, serum SCCA, and CA125 levels in the diagnosis of lymph node metastasis and para-uterine infiltration in cervical cancer
Chao Ran, Jian Sun, Yunhui Qu, Na Long
World Journal of Surgical Oncology.2021;[Epub] CrossRef
A Novel Four-Gene Prognostic Signature as a Risk Biomarker in Cervical Cancer
Jun Wang, Hua Zheng, Yatian Han, Geng Wang, Yanbin Li, Cuida Meng
International Journal of Genomics.2020; 2020: 1. CrossRef

10,363 View
223 Download
14 Web of Science
12 Crossref

Prognostic Model for Survival and Recurrence in Patients with Early-Stage Cervical Cancer: A Korean Gynecologic Oncology Group Study (KGOG 1028): E Sun Paik, Myong Cheol Lim, Moon-Hong Kim, Yun Hwan Kim, Eun Seop Song, Seok Ju Seong, Dong Hoon Suh, Jong-Min Lee, Chulmin Lee, Chel Hun Choi; Cancer Res Treat. 2020;52(1):320-333. Published online August 5, 2019; DOI: https://doi.org/10.4143/crt.2019.124

Abstract PDF PubReader ePub

Purpose
We aimed to develop and validate individual prognostic models in a large cohort of cervical cancer patients that were primarily treated with radical hysterectomy.
Materials and Methods
We analyzed 1,441 patients with early-stage cervical cancer treated between 2000 and 2008 from the Korean Gynecologic Oncology Group multi-institutional cohort: a train cohort (n=788) and a test cohort (n=653). Models predicting the risk for overall survival (OS), disease- free survival (DFS), lymphatic recurrence and hematogenous recurrence were developed using Cox analysis and stepwise backward selection and best-model options. The prognostic performance of each model was assessed in an independent patient cohort. Model-classified risk groups were compared to groups based on traditional risk factors.
Results
Independent risk factors for OS, DFS, lymphatic recurrence, and hematogenous recurrence were identified for prediction model development. Different combinations of risk factors were shown for each outcome with best predictive value. In train cohort, area under the curve (AUC) at 2 and 5 years were 0.842/0.836 for recurrence, and 0.939/0.882 for OS. When applied to a test cohort, the model also showed accurate prediction result (AUC at 2 and 5 years were 0.799/0.723 for recurrence, and 0.844/0.806 for OS, respectively). The Kaplan-Meier plot by proposed model-classified risk groups showed more distinctive survival differences between each risk group.
Conclusion
We developed prognostic models for OS, DFS, lymphatic and hematogenous recurrence in patients with early-stage cervical cancer. Combining weighted clinicopathologic factors, the proposed model can give more individualized predictions in clinical practice.

Citations

Citations to this article as recorded by

External validation of the annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer
Luigi A. De Vitis, Gabriella Schivardi, Aurora Gaeta, Giuseppe Caruso, Marina Rosanu, Lucia Ribero, Diletta Fumagalli, Jvan Casarin, Ilaria Betella, Giorgio Bogani, Carrie L. Langstraat, Giovanni D. Aletti, Nicoletta Colombo, Vanna Zanagnolo, Sara Gandini
International Journal of Gynecological Cancer.2025; : 101756. CrossRef
Stratification by Mutational Landscape Reveals Differential Immune Infiltration and Predicts the Recurrence and Clinical Outcome of Cervical Cancer
Chun Gao, Qian Zhou, Liting Liu, Hong Liu, Yifan Yang, Shen Qu, Qing He, Yafei Huang, Ximiao He, Hui Wang
Phenomics.2025;[Epub] CrossRef
Which factors predict the effectiveness of adjuvant treatment in patients with non-high-risk early-stage cervical cancer? Ancillary analysis of KGOG-1028
Junhwan Kim, Jieun Jang, Myong Cheol Lim, Moon-Hong Kim, Yun Hwan Kim, Eun Seop Song, Seok Ju Seong, Dong Hoon Suh, Jong-Min Lee, Chulmin Lee, Chel Hun Choi, Sokbom Kang
Gynecologic Oncology.2025; 196: 10. CrossRef
Multiparametric MRI-based radiomics nomogram for identifying cervix-corpus junction cervical adenocarcinoma from endometrioid adenocarcinoma
Yuhan Fang, Keying Wang, Meiling Xiao, Jiejun Cheng, Zijing Lin, Jinwei Qiang, Ying Li
Abdominal Radiology.2024; 49(5): 1557. CrossRef
Determination of ovarian transposition through prediction of postoperative adjuvant therapy in young patients with early stage cervical cancer undergoing surgery: a Korean multicenter retrospective study (KGOG 1042)
Woo Yeon Hwang, Chel Hun Choi, Kidong Kim, Moon-Hong Kim, Myong Cheol Lim, Banghyun Lee, Myounghwan Kim, Yun Hwan Kim, Seok Ju Seong, Jong-Min Lee
Obstetrics & Gynecology Science.2024; 67(3): 296. CrossRef
Predictive models for personalized precision medical intervention in spontaneous regression stages of cervical precancerous lesions
Simin He, Guiming Zhu, Ying Zhou, Boran Yang, Juping Wang, Zhaoxia Wang, Tong Wang
Journal of Translational Medicine.2024;[Epub] CrossRef
From the Beginning of the Korean Gynecologic Oncology Group to the Present and Next Steps
Kyung-Jin Min, Nam Kyeong Kim, Jae-Yun Song, Min Chul Choi, Shin Wha Lee, Keun Ho Lee, Min Kyu Kim, Sokbom Kang, Chel Hun Choi, Jeong-Won Lee, Eun-Ju Lee, Keun-Yong Eom, Sang Wun Kim, Hanbyoul Cho, Sun Joo Lee, Myong Cheol Lim, Jaeman Bae, Chong Woo Yoo,
Cancers.2024; 16(19): 3422. CrossRef
Prognostic Factors for Cervical Cancer in Asian Populations: A Scoping Review of Research From 2013 to 2023
Syed S Abrar, Seoparjoo Azmel Mohd Isa, Suhaily Mohd Hairon, Najib M Yaacob, Mohd Pazudin Ismail
Cureus.2024;[Epub] CrossRef
Radiomics based on MRI in predicting lymphovascular space invasion of cervical cancer: a meta-analysis
Chongshuang Yang, Min Wu, Jiancheng Zhang, Hongwei Qian, Xiangyang Fu, Jing Yang, Yingbin Luo, Zhihong Qin, Tianliang Shi
Frontiers in Oncology.2024;[Epub] CrossRef
Systematic review and meta-analysis of prediction models used in cervical cancer
Ashish Kumar Jha, Sneha Mithun, Umeshkumar B. Sherkhane, Vinay Jaiswar, Biche Osong, Nilendu Purandare, Sadhana Kannan, Kumar Prabhash, Sudeep Gupta, Ben Vanneste, Venkatesh Rangarajan, Andre Dekker, Leonard Wee
Artificial Intelligence in Medicine.2023; 139: 102549. CrossRef
Selective photodynamic effects on cervical adenocarcinoma cells provided by F127 Pluronic®-based micelles modulating hypericin delivery
Kayane Harumi Mashiba, Lucimara Rofrigues Carobeli, Maria Vítoria Felipe de Souza, Lyvia Eloiza de Freitas Meirelles, Natália Lourenço Mari, Gabriel Batista César, Renato Sonchini Gonçalves, Wilker Caetano, Edilson Damke, Vânia Ramos Sela da Silva, Gabrie
Brazilian Journal of Pharmaceutical Sciences.2023;[Epub] CrossRef
Optimising follow-up strategy based on cytology and human papillomavirus after fertility-sparing surgery for early stage cervical cancer: a nationwide, population-based, retrospective cohort study
Teska N Schuurman, Mirte Schaafsma, Kaylee H To, Viola M J Verhoef, Karolina Sikorska, Albert G Siebers, Hans H B Wenzel, Maaike C G Bleeker, Eva Maria Roes, Ronald P Zweemer, Peggy J de Vos van Steenwijk, Refika Yigit, Jogchum J Beltman, Petra L M Zuster
The Lancet Oncology.2023; 24(12): 1349. CrossRef
Surgical Treatment for Early Cervical Cancer in the HPV Era: State of the Art
Mario Palumbo, Luigi Della Corte, Carlo Ronsini, Serena Guerra, Pierluigi Giampaolino, Giuseppe Bifulco
Healthcare.2023; 11(22): 2942. CrossRef
Comparison of treatment modalities for selected advanced laryngeal squamous cell carcinoma
Aihemaiti Wushouer, Wenming Li, Minfa Zhang, Dapeng Lei, Xinliang Pan
European Archives of Oto-Rhino-Laryngology.2022; 279(1): 361. CrossRef
The positive threshold of the immunohistochemical parameter Ki67 for predicting the recurrence of cervical cancer
Yuan Tu, Peng Jiang, Jingni Zhang, Shan Jiang, Qianlin Yi, Rui Yuan
International Journal of Gynecology & Obstetrics.2022; 158(2): 330. CrossRef
Management of Early-Stage Cervical Cancer: A Literature Review
Yasmin Medeiros Guimarães, Luani Rezende Godoy, Adhemar Longatto-Filho, Ricardo dos Reis
Cancers.2022; 14(3): 575. CrossRef
The Value of Whole-Tumor Texture Analysis of ADC in Predicting the Early Recurrence of Locally Advanced Cervical Squamous Cell Cancer Treated With Concurrent Chemoradiotherapy
Xiaomiao Zhang, Qi Zhang, Lizhi Xie, Jusheng An, Sicong Wang, Xiaoduo Yu, Xinming Zhao
Frontiers in Oncology.2022;[Epub] CrossRef
The recurrences of cervical cancer: Possibilities of molecular prediction
L. A. Ashrafyan, T. E. Belokrinitskaya, L. F. Sholokhov, E. V. Kayukova, V. A. Mudrov
Acta Biomedica Scientifica.2022; 7(2): 34. CrossRef
Modern diagnostics and treatment of distant metastasis of cervical cancer
R. K. Minyazeva, G. Y. Battalova, I. V. Sakhautdinova, I. R. Gilyazova
Creative surgery and oncology.2022; 12(2): 128. CrossRef
Clinical Outcomes and Their Prognostic Factors among Cervical Cancer Patients with Bone Recurrence
Thiti Atjimakul, Jitti Hanprasertpong, Enrique Hernandez
Obstetrics and Gynecology International.2022; 2022: 1. CrossRef
Adjuvant radiotherapy for cervical cancer in South Korea: a radiation oncology survey of the Korean Radiation Oncology Group (KROG 20-06)
Nalee Kim, Won Park
Japanese Journal of Clinical Oncology.2021; 51(7): 1107. CrossRef
Prediction Models for Prognosis of Cervical Cancer: Systematic Review and Critical Appraisal
Bingjie He, Weiye Chen, Lili Liu, Zheng Hou, Haiyan Zhu, Haozhe Cheng, Yixi Zhang, Siyan Zhan, Shengfeng Wang
Frontiers in Public Health.2021;[Epub] CrossRef
Significance of serum CA125 level in surgically resected cervical adenocarcinoma with adverse features
Nalee Kim, Won Park, Won Kyung Cho, Duk-Soo Bae, Byoung-Gie Kim, Jeong-Won Lee, Chel Hun Choi, Tae-Joong Kim, Yoo-Young Lee
Journal of Gynecologic Oncology.2021;[Epub] CrossRef
The annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer
David Cibula, Lukáš Dostálek, Jiri Jarkovsky, Constantijne H. Mom, Aldo Lopez, Henrik Falconer, Anna Fagotti, Ali Ayhan, Sarah H. Kim, David Isla Ortiz, Jaroslav Klat, Andreas Obermair, Fabio Landoni, Juliana Rodriguez, Ranjit Manchanda, Jan Kosťun, Ricar
European Journal of Cancer.2021; 158: 111. CrossRef
Prognostic Assessment of Cervical Cancer Patients by Clinical Staging and Surgical-Pathological Factor: A Support Vector Machine-Based Approach
Lin Xie, Ran Chu, Kai Wang, Xi Zhang, Jie Li, Zhe Zhao, Shu Yao, Zhiwen Wang, Taotao Dong, Xingsheng Yang, Xuantao Su, Xu Qiao, Kun Song, Beihua Kong
Frontiers in Oncology.2020;[Epub] CrossRef

9,461 View
297 Download
24 Web of Science
25 Crossref

Molecular Signature for Lymphatic Invasion Associated with Survival of Epithelial Ovarian Cancer: E Sun Paik, Hyun Jin Choi, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim, Duk-Soo Bae, Chel Hun Choi; Cancer Res Treat. 2018;50(2):461-473. Published online May 22, 2017; DOI: https://doi.org/10.4143/crt.2017.104

Abstract PDF Supplementary Material PubReader ePub

Purpose
We aimed to develop molecular classifier that can predict lymphatic invasion and their clinical significance in epithelial ovarian cancer (EOC) patients.
Materials and Methods
We analyzed gene expression (mRNA, methylated DNA) in data from The Cancer Genome Atlas. To identify molecular signatures for lymphatic invasion, we found differentially expressed genes. The performance of classifier was validated by receiver operating characteristics analysis, logistic regression, linear discriminant analysis (LDA), and support vector machine (SVM). We assessed prognostic role of classifier using random survival forest (RSF) model and pathway deregulation score (PDS). For external validation,we analyzed microarray data from 26 EOC samples of Samsung Medical Center and curatedOvarianData database.
Results
We identified 21 mRNAs, and seven methylated DNAs from primary EOC tissues that predicted lymphatic invasion and created prognostic models. The classifier predicted lymphatic invasion well, which was validated by logistic regression, LDA, and SVM algorithm (C-index of 0.90, 0.71, and 0.74 for mRNA and C-index of 0.64, 0.68, and 0.69 for DNA methylation). Using RSF model, incorporating molecular data with clinical variables improved prediction of progression-free survival compared with using only clinical variables (p < 0.001 and p=0.008). Similarly, PDS enabled us to classify patients into high-risk and low-risk group, which resulted in survival difference in mRNA profiles (log-rank p-value=0.011). In external validation, gene signature was well correlated with prediction of lymphatic invasion and patients’ survival.
Conclusion
Molecular signature model predicting lymphatic invasion was well performed and also associated with survival of EOC patients.

Citations

Citations to this article as recorded by

Identifying Stage II Colorectal Cancer Recurrence Associated Genes by Microarray Meta-Analysis and Building Predictive Models with Machine Learning Algorithms
Wei Lu, Xiang Pan, Siqi Dai, Dongliang Fu, Maxwell Hwang, Yingshuang Zhu, Lina Zhang, Jingsun Wei, Xiangxing Kong, Jun Li, Qian Xiao, Kefeng Ding, Quan Cheng
Journal of Oncology.2021; 2021: 1. CrossRef

10,220 View
249 Download
5 Web of Science
1 Crossref

Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer: E Sun Paik, Insuk Sohn, Sun-Young Baek, Minhee Shim, Hyun Jin Choi, Tae-Joong Kim, Chel Hun Choi, Jeong-Won Lee, Byoung-Gie Kim, Yoo-Young Lee, Duk-Soo Bae; Cancer Res Treat. 2017;49(3):635-642. Published online September 27, 2016; DOI: https://doi.org/10.4143/crt.2016.282

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study was conducted to evaluate the prognostic significance of pre-treatment complete blood cell count (CBC), including white blood cell (WBC) differential, in epithelial ovarian cancer (EOC) patients with primary debulking surgery (PDS) and to develop nomograms for platinum sensitivity, progression-free survival (PFS), and overall survival (OS).
Materials and Methods
We retrospectively reviewed the records of 757 patients with EOC whose primary treatment consisted of surgical debulking and chemotherapy at Samsung Medical Center from 2002 to 2012. We subsequently created nomograms for platinum sensitivity, 3-year PFS, and 5-year OS as prediction models for prognostic variables including age, stage, grade, cancer antigen 125 level, residual disease after PDS, and pre-treatment WBC differential counts. The models were then validated by 10-fold cross-validation (CV).
Results
In addition to stage and residual disease after PDS, which are known predictors, lymphocyte and monocyte count were found to be significant prognostic factors for platinum-sensitivity, platelet count for PFS, and neutrophil count for OS on multivariate analysis. The area under the curves of platinum sensitivity, 3-year PFS, and 5-year OS calculated by the 10-fold CV procedure were 0.7405, 0.8159, and 0.815, respectively.
Conclusion
Prognostic factors including pre-treatment CBC were used to develop nomograms for platinum sensitivity, 3-year PFS, and 5-year OS of patients with EOC. These nomograms can be used to better estimate individual outcomes.

Citations

Citations to this article as recorded by

The Gustave Roussy immune score as a novel scoring system for predicting platinum resistance in advanced high-grade serous ovarian cancer
Xianglin Nie, Ting Xu, Lin Zhang, Wenjun Cheng
European Journal of Obstetrics & Gynecology and Reproductive Biology.2024; 294: 97. CrossRef
Predictive Value of Machine Learning for Platinum Chemotherapy Responses in Ovarian Cancer: Systematic Review and Meta-Analysis
Qingyi Wang, Zhuo Chang, Xiaofang Liu, Yunrui Wang, Chuwen Feng, Yunlu Ping, Xiaoling Feng
Journal of Medical Internet Research.2024; 26: e48527. CrossRef
Candidate prognostic biomarkers and prediction models for high-grade serous ovarian cancer from urinary proteomics
Maowei Ni, Danying Wan, Junzhou Wu, Wangang Gong, Junjian Wang, Zhiguo Zheng
Journal of Proteomics.2024; 304: 105234. CrossRef
Preoperative Immune Cell Dysregulation Accompanies Ovarian Cancer Patients into the Postoperative Period
Jonas Ulevicius, Aldona Jasukaitiene, Arenida Bartkeviciene, Zilvinas Dambrauskas, Antanas Gulbinas, Daiva Urboniene, Saulius Paskauskas
International Journal of Molecular Sciences.2024; 25(13): 7087. CrossRef
A nomogram with Ki-67 in the prediction of postoperative recurrence and death for glioma
Fengfeng Li, Dongyuan Wang, Nana Wang, Linlin Wu, Bo Yu
Scientific Reports.2024;[Epub] CrossRef
Machine learning for epithelial ovarian cancer platinum resistance recurrence identification using routine clinical data
Li-Rong Yang, Mei Yang, Liu-Lin Chen, Yong-Lin Shen, Yuan He, Zong-Ting Meng, Wan-Qi Wang, Feng Li, Zhi-Jin Liu, Lin-Hui Li, Yu-Feng Wang, Xin-Lei Luo
Frontiers in Oncology.2024;[Epub] CrossRef
Comparison of older and younger patients with ovarian cancer: A post hoc study (JGOG3016‐A3) of the treatment strength and prognostic outcomes of conventional or dose‐dense chemotherapy
Yoshio Itani, Hitomi Sakai, Tetsutaro Hamano, Mikiko Asai‐Sato, Masayuki Futagami, Masaki Fujimura, Yoichi Aoki, Nao Suzuki, Yoshio Yoshida, Takayuki Enomoto
Journal of Obstetrics and Gynaecology Research.2023; 49(5): 1400. CrossRef
Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives
Stanislas Quesada, Michel Fabbro, Jérôme Solassol
Cancers.2022; 14(4): 1098. CrossRef
Development of Machine Learning Models to Predict Platinum Sensitivity of High-Grade Serous Ovarian Carcinoma
Suhyun Hwangbo, Se Ik Kim, Ju-Hyun Kim, Kyung Jin Eoh, Chanhee Lee, Young Tae Kim, Dae-Shik Suh, Taesung Park, Yong Sang Song
Cancers.2021; 13(8): 1875. CrossRef
Beyond BRCA Status: Clinical Biomarkers May Predict Therapeutic Effects of Olaparib in Platinum-Sensitive Ovarian Cancer Recurrence
Kazuho Nakanishi, Takashi Yamada, Gen Ishikawa, Shunji Suzuki
Frontiers in Oncology.2021;[Epub] CrossRef
Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study
Alberto Farolfi, Emanuela Scarpi, Filippo Greco, Alice Bergamini, Lucia Longo, Sandro Pignata, Claudia Casanova, Gennaro Cormio, Alessandra Bologna, Michele Orditura, Laura Zavallone, Laura Attademo, Valentina Gallà, Elisena Franzese, Eva Pigozzi, Vera Lo
Scientific Reports.2020;[Epub] CrossRef
Pertinence des marqueurs tumoraux, scores (cliniques et biologiques) et algorithmes à visée diagnostique et pronostique devant une masse ovarienne suspecte d’un cancer épithélial. Article rédigé sur la base de la recommandation nationale de bonnes pratiqu
S. Bendifallah, G. Body, E. Daraï, L. Ouldamer
Gynécologie Obstétrique Fertilité & Sénologie .2019; 47(2): 134. CrossRef
Development of Web-Based Nomograms to Predict Treatment Response and Prognosis of Epithelial Ovarian Cancer
Se Ik Kim, Minsun Song, Suhyun Hwangbo, Sungyoung Lee, Untack Cho, Ju-Hyun Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Dae-Shik Suh, Taesung Park, Yong-Sang Song
Cancer Research and Treatment.2019; 51(3): 1144. CrossRef

11,711 View
283 Download
14 Web of Science
13 Crossref

First
Prev
Page of 1
Next
Last

Search